

## **NHS ENGLAND SPECIALISED SERVICES**

### **CLINICAL PANEL REPORT**

Date: March 2020

Intervention: Brachytherapy dose escalation with external beam radiotherapy

Indication: intermediate and high risk localised prostate cancer (adults)

ID: 1831

Gateway: 2 Round 3

Programme: Cancer

CRG: Radiotherapy

---

#### **Information provided to the panel**

Clinical Panel Reports from Gateway 2 (Round 1 & 2)

Evidence Review undertaken by Solutions for Public Health x 2 – high dose and low dose

Clinical Priorities Advisory Group (CPAG) Summary Report

Policy Proposition

PWG Membership Appendix

---

#### **Key elements discussed**

This proposition is proposed for routine commissioning.

This was previously considered by the Clinical Panel in April and October 2019. At the request of Clinical Panel the policy proposition had been significantly revised for clarity. It was also noted that the two CPAG summary reports previously presented to Panel have been amalgamated in to one document, as requested.

The 3<sup>rd</sup> paragraph in the 'About current treatments' section of the proposition was previously not considered to be written clearly enough to demonstrate the indication is localised prostate cancer. Panel were now content with the amendments made.

Clinical Panel was satisfied that the proposition now gave clinicians appropriate guidance regarding which patients could receive high dose therapy and who could receive low dose therapy.

Clinical Panel noted the inclusion of a Shared Decision-Making tool but raised concerns about usability due to inclusion of technical language and limited detail on risks. Panel advised this would have to undergo further testing to ensure it is user friendly. It was agreed that the Programme of Care would work with charity partners to test the tool and the Panel Chair and National Clinical Director for Cancer would sign off any further amendments.

---

## **Recommendation**

The Panel recommended that the policy proposition proceed to stakeholder testing as a for routine commissioning proposition, as stated.

---

## **Why the panel made these recommendations**

The Clinical Panel considered that the policy proposition had been substantially improved and is in line with the presented evidence base.

---

## **Documentation amendments required**

Policy Proposition:

- Shared decision tool to undergo further testing and revision
- 

Declarations of Interest of Panel Members: A member of the Panel who has a personal relationship with a clinician who may treat this patient group. A member of the Panel has a speciality that may treat some of these patients.

Panel Chair: James Palmer, Medical Director Specialised Services

## **Post Panel note:**

Shared decision tool revised following engagement with charity partner organisation.